Biosimilar ranibizumab measures up to original for nAMD
19 May 2021
byJairia Dela Cruz
In the treatment of patients with neovascular age-related macular degeneration (nAMD), the biosimilar FYB201 appears to have similar efficacy, safety, and immunogenicity as ranibizumab, as shown in the results of a phase III study.